Ken Berlin
President & CEO
Claimed by owner Ayala Pharmaceuticals
Former names:
Targeted Therapies for People with Genetic Cancers
Acquired by Advaxis on Jan, 2023
Ayala Pharmaceuticals
www.globenewswire.com
•
Feb 10, 2023
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
www.globenewswire.com
•
Jan 19, 2023
Advaxis and Ayala Pharmaceuticals Complete Merger
www.globenewswire.com
•
Nov 16, 2022
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
www.globenewswire.com
•
Oct 19, 2022
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
en.globes.co.il
•
May 10, 2020
Ayala Pharmaceuticals raises $55m in Nasdaq IPO
www.globenewswire.com
•
May 7, 2020
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
en.globes.co.il
•
Mar 8, 2020
Ayala Pharma files for Nasdaq IPO
www.businesswire.com
•
Mar 3, 2020
Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
www.calcalistech.com
•
Jan 7, 2020
Ayala Pharmaceuticals Headed for Nasdaq IPO
www.businesswire.com
•
Sep 30, 2019
Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
www.businesswire.com
•
Sep 19, 2019
Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)
www.fiercebiotech.com
•
Sep 9, 2019
Ayala Pharma nabs AbbVie cancer exec Gordon as CMO
www.prnewswire.com
•
Jul 8, 2019
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
en.globes.co.il
•
May 28, 2019
Cancer drug developer Ayala Pharmaceuticals raises $30m
www.businesswire.com
•
May 24, 2019
Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
apnews.com
•
May 20, 2019
Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer
www.apnews.com
•
May 13, 2019
FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)
www.apnews.com
•
Mar 6, 2019
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
www.calcalistech.com
•
Dec 24, 2018
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
www.marketwatch.com
•
Dec 20, 2018
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20
www.marketwatch.com
•
Dec 17, 2018
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17
www.globes.co.il
•
Apr 11, 2018
Cancer drug developer Ayala Pharmaceuticals raises $17m
www.businesswire.com
•
Dec 6, 2017
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
About
Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing potential small molecule therapeutics for patients suffering from rare and aggressive cancers, especially in genetically defined patient populations.
Ayalas product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). By developing drugs designed to inhibit Notch pathway activation, Ayala is enabling personalized therapy for cancer patients.
In 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors. Ayalas lead product, AL101, granted orphan drug designation by the FDA in 2019, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma bearing activated Notch mutations has been initiated.
In 2018, Ayala entered into a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in hematologic cancers.
Ayalas product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). By developing drugs designed to inhibit Notch pathway activation, Ayala is enabling personalized therapy for cancer patients.
In 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors. Ayalas lead product, AL101, granted orphan drug designation by the FDA in 2019, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma bearing activated Notch mutations has been initiated.
In 2018, Ayala entered into a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in hematologic cancers.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
BMS-986115, AL102, AL101, BMS-906024
Geographic markets
United States
News
(23)
www.globenewswire.com
•
Feb 10, 2023
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
www.globenewswire.com
•
Jan 19, 2023
Advaxis and Ayala Pharmaceuticals Complete Merger
www.globenewswire.com
•
Nov 16, 2022
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
www.globenewswire.com
•
Oct 19, 2022
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
en.globes.co.il
•
May 10, 2020
Ayala Pharmaceuticals raises $55m in Nasdaq IPO
www.globenewswire.com
•
May 7, 2020
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
en.globes.co.il
•
Mar 8, 2020
Ayala Pharma files for Nasdaq IPO
www.businesswire.com
•
Mar 3, 2020
Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
www.calcalistech.com
•
Jan 7, 2020
Ayala Pharmaceuticals Headed for Nasdaq IPO
www.businesswire.com
•
Sep 30, 2019
Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
www.businesswire.com
•
Sep 19, 2019
Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)
www.fiercebiotech.com
•
Sep 9, 2019
Ayala Pharma nabs AbbVie cancer exec Gordon as CMO
www.prnewswire.com
•
Jul 8, 2019
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
en.globes.co.il
•
May 28, 2019
Cancer drug developer Ayala Pharmaceuticals raises $30m
www.businesswire.com
•
May 24, 2019
Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
apnews.com
•
May 20, 2019
Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer
www.apnews.com
•
May 13, 2019
FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)
www.apnews.com
•
Mar 6, 2019
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
www.calcalistech.com
•
Dec 24, 2018
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
www.marketwatch.com
•
Dec 20, 2018
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20
www.marketwatch.com
•
Dec 17, 2018
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17
www.globes.co.il
•
Apr 11, 2018
Cancer drug developer Ayala Pharmaceuticals raises $17m
www.businesswire.com
•
Dec 6, 2017
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
The Team
(4)
KB
DG
Dana Gelbaum
CBO
DC
David Caron
VP CMC
IK
Irit Klipper-Avni
VP HR
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$55M
May 2020
Stock Exchange
NASDAQ
Valuation
Undisclosed
$55M
M&A
Undisclosed
Jan 2023
Type
Merger
Merged to
Advaxis
Undisclosed
Private Equity Funding
Seed
Undisclosed
Dec 2017
3 Investors
Undisclosed
A Round
$17M
Apr 2018
3 Investors
$17M
B Round
$30M
May 2019
6 Investors
$30M
Non-Equity Funding
Grant
Undisclosed
Dec 2017
1 Grantors
Undisclosed
Media gallery
(0)Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel
Offices Abroad
1007 North Orange Street, Wilmington, DE, USA
Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel
Offices Abroad
1007 North Orange Street, Wilmington, DE, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,